Celltrion's rheumatoid arthritis drug meets both endpoints in PhIII; New company Tribune emerges to take on fibrotic diseases
Celltrion Healthcare announced positive results from its year-long Phase III trial of its rheumatoid arthritis drug Yuflyma in patients receiving therapy on Tuesday, as the trial met both the primary and secondary endpoints.
The trial in patients with moderate-to-severe RA tested 3 groups: 1 in patients who received 40 mg of CT-P17 or 1 that received the reference drug Humira, and a third that switched from Humira to CP-P17 halfway through the trial, for the remainder of the year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.